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Conclusions: Sub-optimal TIMI flow is of greater prognostic value in DP compared to
N-DP, stressing the importance of optimal reperfusion after primary PCI for STEMI in DM.
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Background: The purpose of this study was to assess the impact of body mass index
(BMI) and diabetes mellitus (DM) on angiographic outcomes in patients treated with
different drug-eluting stents.
Methods: From November 2002 to March 2011, 8567 de novo coronary lesions
were treated with drug-eluting stent. Dialysis patients were excluded. Of 8567
lesions, 1934 lesions were treated with everolimus-eluting stent (EES), 1215 with
paclitaxel-eluting stent (PES), and 5418 with sirolimus-eluting stent (SES).
Angiographic follow-up was routinely performed at 8 months after successful
procedure. The follow-up rate was 81%. The patients were classified as under-
weight (BMI 20), normal weight (BMI 20 and 25), and overweight (BMI
25). The patients were divided into three groups according to implanted stent
type: EES, PES, and SES. Of all patients, 42% were with DM, of whom 11% were
insulin-dependent. The rates of DM and insulin treatment were similar in all
groups. Angiographic outcomes were compared between each group.
Results: Independent predictors of binary restenosis differed in each group. In the
SES group, they were BMI (depression of 5 kg/m2), DM, bifurcation, chronic
total obstruction (CTO), stent size 2.5 mm, and lesion length 20 mm. In the PES
group, they were BMI (depression of 5 kg/m2), DM, and stent size 2.5 mm. In the
EES group, they were CTO, stent size 2.5 mm, and lesion length 20 mm. The
figure shows odds ratio of BMI (depression of 5 kg/m2) and DM between each
group.
Conclusions: BMI and DM affect angiographic outcomes in patients treated with SES
and PES but not those in patients treated with EES.
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Background: Diabetes mellitus is known as a strong predictive factor of adverse
cardiovascular event after ST-segment elevation myocardial infarction (STEMI). Re-
cently, glycosylated hemoglobin (HbA1c) reflecting serum glucose control within 8 to 12
weeks, is studied to investigate relationship with major adverse cardiac events (MACE)
after acute myocardial infarction. This study is conducted to determine the association
between follow-up HbA1c and MACE in diabetic patients with STEMI undergoing
primary percutaneous coronary intervention (PCI).
Methods: Using data from Korea Working Group on Myocardial Infarction, 303
diabetic patients with STEMI undergoing primary PCI were enrolled. Patients
were divided into three groups based on follow-up HbA1c(FU-HbA1c): optimal,
FU-HbA1c 7%; suboptimal, 7%FU-HbA1c9%, poor controlled group,
9%FU-HbA1c. We analyzed 12-month cumulative MACE, defined as a com-
posite of mortality, nonfatal myocardial infarction, re-PCI or coronary artery
bypass graft in each group. Also, we investigated the value of FU-HbA1c to
predict MACE using multivariate logistic regression analysis.
Results: The mean duration of HbA1c and clinical event follow-up was 5 and 12 months,
respectively. The incidence rate of 12-month cumulative MACE were significantly
different in each group: 7.3% vs 13.0% vs 23.9%, respectively (p0.005), which was
mainly due to increased repeated PCI. In multivariate logistic analysis, the factor of
FU-HbA1c more than 9.0% was shown to be independently associated with 12-month
cumulative MACE, and compared with FU-HbA1c7.0%: OR 11.437, 95% confidence
interval 1.709-76.522, p0.012.
Conclusions: This study suggests that FU-HbA1c in early phase was associated
with higher incidence of 12-month cumulative MACE, mainly contributing to
increased repeated PCI in diabetic patients with STEMI undergoing primary PCI.
And more than 9% of FU-HbA1c was identified to be an independent predictor of
adverse outcome. These imply continuous tight monitoring of serum glucose in
early phase after myocardial ischemic insult is important to reduce the possibility
of repeated PCI following restenosis, but more research is needed to understand
these findings with long-term clinical data.
TCT-347
Clinical Outcome Of Biolimus-Eluting Versus Sirolimus-Eluting Coronary
Stent Implantation In Patients With And Without Diabetes Mellitus: A SORT
OUT V Substudy
Michael Maeng1, Evald Christiansen2, Hans-Henrik Tilsted3, Jan Ravkilde3,
Per Thayssen4, Lisette Jensen4, Morten Madsen1, Lars Krusell5,
Hans Erik Bøtker6, Leif Thuesen7, Jens Flensted Lassen8
1Aarhus University Hospital, Aarhus, Denmark, 2Department of Cardiology,
Aarhus University Hospital, Skejby, Aarhus N, Denmark, 3Aarhus University
Hospital, Aalborg, Aalborg, Denmark, 4Department of Cardiology, Odense
University Hospital, Odense, Denmark, 5Aarhus University Hospital, Skejby,
Aarhus, Denmark, 6Aarhus University Hospital, Skejby, Aarhus N, Denmark,
7Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus,
Denmark, 8Aarhus University, Aarhus, Denmark
Background: Diabetes is associated with an increased risk of major adverse cardiac
events (MACE) following percutaneous coronary intervention.
Methods: We compared clinical outcomes in patients with and without diabetes
mellitus treated with the third-generation biolimus-eluting Nobori stent (BES) or
the first-generation sirolimus-eluting Cypher™ Select	 stent (SES) in the SORT
OUT V trial. We randomized 2.468 patients to treatment with BES (n1.229,
diabetes: n185) or SES (n1.239, diabetics: n189) and followed them for 12
months. Randomization was stratified by presence/absence of diabetes. The
primary endpoint was MACE, defined as a composite of cardiac death, myocardial
infarction (MI), or target vessel revascularization (TVR). Secondary endpoints
were each of these individual endpoints plus all-cause mortality, target lesion
revascularization (TLR), and definite stent thrombosis.
Results: In diabetic patients, use of BES compared with SES was neither
associated with an increased risk of MACE (6.6% vs. 8.0%; hazard ratio (HR) 
0.83, 95% confidence interval (CI): 0.39-1.77), MI (1.6% vs. 1.6%, HR  1.02,
95% CI: 0.21-5.08), TVR (5.9% vs. 4.8%; HR  1.27, 95% CI: 0.52-3.05), nor
TLR (5.4% vs. 3.2%; HR  1.72, 95% CI: 0.63-4.74). Similarly, patients without
diabetes, MACE (5.1% vs. 3.7%; hazard ratio (HR)  1.38, 95% CI: 0.91-2.08.),
MI (1.4% vs. 0.8%, HR  1.89, 95% CI: 0.80-4.47), TVR (3.8% vs. 2.8%; HR 
1.40, 95% CI: 0.87-2.25), and TLR (2.8% vs. 1.8%; HR  1.55, 95% CI: 0.87-2.76)
showed no differences between the two stents. With regard to definite stent
thrombosis, BES was neither associated with fewer events in patients with diabetes
(2.2% vs. 1.2%; HR  2.05, 95% CI: 0.38-11.2) nor in patients without diabetes
(0.6% vs. 0.2%; HR  3.03, 95% CI: 0.61-15.0).
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Conclusions: Coronary implantation of BES or SES is associated with similar event rates
at 12-month follow-up in patients with, and without, diabetes.
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Background: The aim of this study is to compare the safety and efficacy of Sirolimus
(SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES-R/ Endeavor Resolute),
BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of percutaneous
coronary intervention in patients with diabetes mellitus (DM).
Methods: A prospective analysis of 2972 patients with DM (808 SES, 720 PES,
299 ECS, 404 ZES-R, 320 BES, 421 EES) in six high volume Asian centers after
successful stenting was performed. The study endpoints were 30 days major
adverse cardiac events (MACE) and 12, 24 and 36 months target lesion
revascularization (TLR) and MACE.
Results: See table for clinical results.
Conclusions: The use of drug-eluting stents in patient with DM was safe with low acute
complication. Patients treated with BES and EES showed lesser rate of restenosis
compared with ECS.
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Background: The aim of this study is to compare the safety and efficacy of Sirolimus
(SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES),
EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of treatment of
small coronary artery disease with diabetes mellitus (DM).
Methods: A prospective analysis of 1670 patients with diabetic small coronary artery
stenosis (420 SES, 360 PES, 249 ZES, 200 BES, 153 ECS, 288 EES) in six high volume
Asian centers after successful stent implantation was performed. The study endpoints
were major adverse events (MACE) at 30 days, 12 months restenosis rate and target lesion
revascularization (TLR) at 12 months.
Results: See table for clinical results.
Conclusions: The use of drug-eluting stents in patients with diabetic small coronary
artery stenosis was safe and feasible. Patients treated with BES and EES showed lesser
rate of restenosis compared with ECS.
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Background: The aim of this study is to compare the safety and efficacy of
Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES-R/ Endeavor Resolute),
BiolimusA9 (BES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the
outcome of stenting in patients with diabetic very long coronary lesion (VLL)
(lesion length 40 mm).
Methods: A prospective analysis of 1317 patients with diabetic VLL (328 SES, 280 PES,
189 ZES-R, 190 BES, 143 ECS, 187 EES) was performed. The study endpoints were
major adverse cardiac events (MACE) at 12 months, restenosis rate and target lesion
revascularization (TLR) at 12 months.
Results: See table for clinical results.
Conclusions: (1) The use of drug-eluting stents in patients with diabetic VLL seems to
be favorable in terms of in-hospital clinical outcome and long-term results. (2) Patients
treated with BES and EES showed lesser restenosis rate and TLR compared with PES and
ECS.
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